Sign in

CIK 0001841387

  • Emerging growth company

Candel Therapeutics, Inc.

Sign in to watch
Ticker
CADL
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
522214851
Phone
+1 617-916-5445
Business address
117 KENDRICK STREET, SUITE 450, NEEDHAM, MA, 02494
  1. 4 Returned to the company 10% owner returned 350,000 shares (to the company)
  2. 4 Open-market buy Director bought 1,250,000 shares at $6.00 ($7,500,000)
  3. 4 Returned to the company 10% owner returned 800,000 shares (to the company)
  4. 4 Returned to the company 10% owner returned 60,000 shares (to the company)
  5. 4 Open-market sale Chief Technology Officer sold 20,392 shares at $4.56 ($92,898)
  6. 4 Open-market sale Chief Executive Officer sold 48,847 shares at $4.56 ($222,527)
  7. 4 Open-market sale Chief Medical Officer sold 13,935 shares at $4.56 ($63,482)
  8. 4 Open-market sale Chief Scientific Officer sold 22,081 shares at $4.56 ($100,592)
  9. 4 Returned to the company 10% owner returned 20,000 shares (to the company)
  10. 4 Option exercise Chief Executive Officer acquired 12,900 shares (option exercise)
  11. 4 Returned to the company 10% owner returned 45,000 shares (to the company)
  12. 4 Returned to the company 10% owner returned 42,000 shares (to the company)
  13. 4 Returned to the company 10% owner returned 30,929 shares (to the company)
  14. 4 Open-market sale 10% owner sold 40,412 shares at an average $6.03 ($243,834)
  15. 4 Open-market sale 10% owner sold 28,788 shares at an average $6.92 ($199,087)
  16. 4 Open-market sale Chief Technology Officer sold 14,851 shares at $6.47 ($96,125)
  17. 4 Open-market sale Chief Executive Officer sold 22,528 shares at $6.47 ($145,815)
  18. 4 Open-market sale See Remarks sold 9,884 shares at $6.47 ($63,975)
  19. 4 Open-market sale Chief Medical Officer sold 10,875 shares at $6.47 ($70,390)
  20. 4 Open-market sale Chief Scientific Officer sold 14,051 shares at $6.47 ($90,947)

Page 5 of 11 · 202 filings